Can Test Reports Be Reused for Medical Device Registration in Japan?

Direct answer: Test reports and other documents prepared for medical device registration in Japan are generally not reusable as-is. Reuse — whether in full or in part — can only be determined after the company has confirmed the target market, the product's risk class, the applicable regulatory pathway and the existing documentation base, and has then assessed the technical file, quality management system evidence, labelling and instructions for use (IFU), local marketing authorization holder arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing evidence or unresolved authorization arrangements do not extend the project timeline.

Published: 2026-07-15 18:51 | Updated: 2026-07-15 18:51

Executive Summary

On the question of whether test reports from medical device registration in Japan can be reused, companies should first confirm the target country, the product risk class, the applicable regulatory pathway and the existing documentation base, and then evaluate the technical file, quality system, labelling and IFU, local agent arrangements, clinical evidence and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, incomplete documentation or undefined authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete a product classification and documentation gap assessment first, and only then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects the technical file, authorized representative, importer cooperation, label language, quality system evidence and subsequent change control at the same time. If a project is driven only by the question of which documents to submit, deficiencies and rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding documentation from scratch for each country.

Scope of Application and Core Questions

Companies searching for information on whether test reports from medical device registration in Japan can be reused are usually not looking for a conceptual explanation. They are trying to determine whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines are extended, and which issues may affect the launch plan. This question typically involves product classification, regulatory pathway, evidence chain, label localization and post-market maintenance responsibilities at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America simultaneously, answering the question for one country alone is not sufficient. A more valuable approach is to first prepare a reusable version of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localize it according to each country's regulatory requirements.

Regulatory Assessment Logic

Companies should first confirm the intended use, mechanism of action, use environment, mode of body contact, duration of use, sterility, whether the device is active, and whether it contains software or has IVD characteristics, and then determine the risk class and submission pathway. Once the pathway assessment is wrong, all downstream activities — translation, notarization, authorization, testing and supplementary responses — will move in the wrong direction.

For a target market project, the applicant entity and local responsibility boundaries must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who initiates changes, and who maintains documentation for certificate renewal. If these points are left ambiguous in commercial contracts, market control can be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or other applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Mistakes

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly without restructuring the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to verify their documentation base against an internal checklist, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English-language IFU.
• Confirm the duties, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by supplementary declarations.

AIMEILI's View

AIMEILI advises companies not to treat registration in a target market as a one-off document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to subsequent changes and certificate renewals than preparing documentation on an ad hoc basis country by country.

From a project management perspective, three items should be controlled at the earliest stage: first, product classification and pathway determination; second, consistency of the documentation and evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project may still encounter repeated deficiencies, agent communication issues and post-market maintenance problems, even when a large volume of documentation appears to be available.

Common Follow-up Questions

Can domestic documentation be used directly for registration in a target market?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as-is. Companies must adjust the documentation structure, language, labelling, authorization documents and evidence chain in accordance with local regulatory requirements.

When is the best time to start a gap assessment?

It should be started as soon as the target market and product list have been confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in regulatory communication, change filings, certificate renewal and post-market event handling. Unclear responsibilities affect certificate control and long-term market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, models and specifications, regulatory pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also establish an evidence reuse matrix defining which documents can serve as core evidence and which must be reissued or supported by supplementary statements for specific countries. Labelling and IFU, clinical evaluation, risk management, performance verification and quality system certificates must in particular remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope of the ISO 13485 certificate does not match the products being submitted, or if the manufacturing address, models and specifications, or IFU version do not align with the test reports, the company may be asked for supplementary explanations even if it has already prepared a large volume of documentation.

Companies should establish an evidence consistency check table before submission, mapping product name, models and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labelling and IFU version, and quality system certificates item by item. This step may appear basic, but it can significantly reduce the likelihood of deficiencies, especially for projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization and Agent Responsibilities

Registration projects in a target market usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies must confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labelling and IFU, as well as authorization documents, cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into an application structure acceptable in the target country, rather than drafting a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration is not the end of compliance work. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest substantial effort in obtaining a certificate but neglect post-market maintenance; if a manufacturing address change, model extension, IFU update or agent replacement occurs later, the certificate can easily become disconnected from actual market sales.

AIMEILI recommends managing this question within an annual international registration plan: first define market priorities, then build a reusable documentation package and a country-specific gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only improved efficiency for a single country registration, but also the development of a replicable compliance capability for overseas expansion, reducing the cost of rebuilding documentation from scratch each time a new market is entered.

Further Reading

• Previous: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Japan?
• Next: How Is an ISO 13485 Certificate Used in Medical Device Registration in Japan?
• Recommended: How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• Recommended: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Recommended: Why Do Medical Device Registration Timelines in Brazil Become Extended?
• Recommended: What Are the Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• Recommended: How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• Recommended: When Must Registration Changes Be Filed for Medical Device Registration in Brazil?
• Back to the FAQ Centre
• News and Insights
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.